Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 596 in EGFRvIII-Positive Glioblastoma
NCT03296696Phase 1Terminated
- Sponsor
- Amgen
- Start
- Apr 2018
- Primary completion
- Jul 2021
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 6
01
Overview
Phase 1, open-label trial of etevritamab in glioblastoma (GBM) and malignant glioma (2 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment Emergent Adverse Events and 1 more. Started Apr 2018; status: terminated.
02
Drugs
etevritamab
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT03296696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296696.